Literature DB >> 28380485

Subclinical Atherosclerosis in Patients with Prior Pulmonary Thromboembolism.

Zafer Buyukterzi, Meral Buyukterzi, Ercan Kurtipek, Mehmet Sertac Alpaydin, Sukru Karaarslan.   

Abstract

OBJECTIVE: Recent studies have indicated that endothelial dysfunction is common in patients with a prior history of pulmonary thromboembolism (PTE). Based on the established relationship between endothelial dysfunction and atherosclerosis, we aimed to investigate carotid intima-media thickness (cIMT) as a marker of subclinical atherosclerosis in patients who have a prior history of PTE. SUBJECTS AND METHODS: Medical records belonging to patients with a history of PTE and age- and gender-matched control subjects among those who underwent transthoracic echocardiography in Konya Training and Research Hospital were reviewed. Echocardiographic findings and cIMT measurements were recorded. cIMT measurements were compared between patient and control groups, and then independent correlates of cIMT were investigated using appropriate statistical methods.
RESULTS: A total of 110 patients (64.02 ± 12.67 years, males: n = 79 [71.81%]; females: n = 31 [28.19%]) were found to be eligible for assessment. Of these patients, 55 (50.00%) had a history of PTE. Patients with a history of PTE had significantly greater cIMT (p = 0.040). In this group of patients, cIMT positively and significantly correlated with basal right ventricular (RV) diameter (r = 0.271, p = 0.022), RV diastolic area (r = 0.376, p = 0.002), and systolic pulmonary artery pressure (r = 0.248, p = 0.037). In the multivariate linear regression analysis, only RV diastolic area was independently associated with cIMT in patients with PTE (p = 0.010).
CONCLUSION: Patients with a history of PTE have increased cIMT when compared to healthy subjects, and cIMT, which is a marker of subclinical atherosclerosis, is independently associated with RV diameter in these patients.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Carotid intima-media thickness; Pulmonary thromboembolism; Subclinical atherosclerosis

Mesh:

Year:  2017        PMID: 28380485      PMCID: PMC5768129          DOI: 10.1159/000475466

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  17 in total

1.  Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.

Authors:  Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller
Journal:  J Am Soc Echocardiogr       Date:  2010-07       Impact factor: 5.251

2.  Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension.

Authors:  H Kimura; O Okada; N Tanabe; Y Tanaka; M Terai; Y Takiguchi; M Masuda; N Nakajima; K Hiroshima; H Inadera; K Matsushima; T Kuriyama
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

Review 3.  Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding.

Authors:  Irene M Lang; Raffaele Pesavento; Diana Bonderman; Jason X-J Yuan
Journal:  Eur Respir J       Date:  2012-06-14       Impact factor: 16.671

Review 4.  Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective.

Authors:  Seiichiro Sakao; Koichiro Tatsumi
Journal:  Histol Histopathol       Date:  2013-02       Impact factor: 2.303

5.  Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension.

Authors:  Herre J Reesink; Ronald C Meijer; René Lutter; Frans Boomsma; Henk M Jansen; Jaap J Kloek; Paul Bresser
Journal:  Circ J       Date:  2006-08       Impact factor: 2.993

6.  Endothelin abnormalities in patients with pulmonary embolism.

Authors:  M Sofia; S Faraone; M Alifano; A Micco; R Albisinni; M Maniscalco; G Di Minno
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

7.  Endothelial dysfunction in patients with pulmonary thromboembolism: neutrophil to lymphocyte ratio and platelet to lymphocyte ratio.

Authors:  Ercan Kurtipek; Zafer Büyükterzi; Meral Büyükterzi; Mehmet Sertaç Alpaydın; Said Sami Erdem
Journal:  Clin Respir J       Date:  2015-06-02       Impact factor: 2.570

8.  Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism.

Authors:  Pierre-Marie Roy; Guy Meyer; Bruno Vielle; Catherine Le Gall; Franck Verschuren; Françoise Carpentier; Philippe Leveau; Alain Furber
Journal:  Ann Intern Med       Date:  2006-02-07       Impact factor: 25.391

9.  Assessment of inflammatory biomarkers and oxidative stress in pulmonary thromboembolism: follow-up results.

Authors:  Bilal Halici; Sevinc Sarinc Ulasli; Ersin Günay; Serkan Nural; Serkan Sen; Olcay Akar; Sefa Celik; Mehmet Unlu
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

10.  High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension.

Authors:  Diana Bonderman; Peter L Turecek; Johannes Jakowitsch; Ansgar Weltermann; Christopher Adlbrecht; Barbara Schneider; Meinhard Kneussl; Lewis J Rubin; Paul A Kyrle; Walter Klepetko; Gerald Maurer; Irene M Lang
Journal:  Thromb Haemost       Date:  2003-09       Impact factor: 5.249

View more
  3 in total

1.  A Case of Massive Cerebral Arterial Air Embolism Induced by Artificial Pneumothorax and Its Analysis.

Authors:  Xiao-Hua Gou; Wei Yang; Yan-Li Zhang; Ya Li; Xin Wu
Journal:  Med Princ Pract       Date:  2018-12-19       Impact factor: 1.927

2.  Reply.

Authors:  Zafer Buyukterzi; Mehmet Sertac Alpaydin
Journal:  Med Princ Pract       Date:  2018-07-10       Impact factor: 1.927

3.  Right Ventricular Functions in Pulmonary Thromboembolism.

Authors:  Tarik Yildirim; Fatih Akin; Ibrahim Altun; Seda Elcim Yildirim; Ozcan Basaran; Mustafa Ozcan Soylu
Journal:  Med Princ Pract       Date:  2018-04-05       Impact factor: 1.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.